-
The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma. Pediatr Blood Cancer. 2026 Apr; 73(4):e70152. Papyan R, Hoveyan J, Guscott M, Lowe J, Villanueva G, Streby KA, Tadevosyan E, Demirtshyan E, Hylton J, Tamamyan G, Lam CG, Matthay K, Howard SC. PMID: 41574962.
-
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project. JCO Glob Oncol. 2025 Dec; 11:e2500349. London WB, Villanueva G, Shyr D, van Heerden J, Fuentes-Alabi S, Saab R, Harrison D, Papyan R, Kim Nguyen HT, Noun D, Kambugu J, Rascon J, Garami M, Guo D, Kao P, Naranjo A, Park JR, Cohn SL, Rodriguez-Galindo C, Matthay KK. PMID: 41435213.
-
International neuroblastoma risk group consortium: a model of a networking for rare cancers. J Natl Cancer Inst. 2025 Aug 25. Cohn SL, London WB, Schleiermacher G, Moreno L, Ambros IM, Ambros PF, Bagatell R, Popovicmd MB, Beiske KH, Berthold F, Birz S, Brisse HJ, Brodeur GM, Brock PR, Burchill S, Eggert A, Federico SM, Fischer M, Furner BT, Hero B, Machin D, Kamijo T, Matthay KK, Nakagawara A, Naranjo A, Pötschger U, Valteau-Couanet D, Watkins MT, Irwin MS, Volchenboum SL, Park JR, Pearson ADJ. PMID: 40854111.
-
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 Aug; 43(22):2490-2501. Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC. PMID: 40549985; PMCID: PMC12226806.
-
Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Res. 2024 Oct 01; 84(19):3311. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. PMID: 39350668.
-
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. EJNMMI Res. 2024 Jun 13; 14(1):54. Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. PMID: 38869684; PMCID: PMC11176152.
-
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug; 71(8):e31089. Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. PMID: 38822537; PMCID: PMC11318088.
-
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul; 71(7):e31039. Kumar P, Willard VW, Embry L, Naranjo A, LaBarre B, Matthay KK, de Alarcon PA. PMID: 38689540; PMCID: PMC11116037.
-
ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Rep. 2024 03 26; 43(3):113927. Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, Wang L, Asgharzadeh S, Park J, Gustafson WC, Matthay KK, Maris JM, Weiss WA. PMID: 38451815; PMCID: PMC11101011.
-
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Res Sq. 2024 Jan 18. Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. PMID: 38313265; PMCID: PMC10836112.
-
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. Br J Cancer. 2024 03; 130(5):788-797. Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. PMID: 38200233; PMCID: PMC10912730.
-
Pediatric neuroblastoma with intraspinal extension: the role of surgical management. J Neurosurg Pediatr. 2024 03 01; 33(3):245-255. Chang D, Oh T, Roland JL, Matthay KK, Vo KT, Edwards CS, Sun PP, Auguste KI, Gupta N. PMID: 38100763.
-
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30743. Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. PMID: 37885116; PMCID: PMC10842219.
-
Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Cell Rep. 2023 08 29; 42(8):112879. Rosenberg MI, Greenstein E, Buchkovich M, Peres A, Santoni-Rugiu E, Yang L, Mikl M, Vaksman Z, Gibbs DL, Reshef D, Salovin A, Irwin MS, Naranjo A, Ulitsky I, de Alarcon PA, Matthay KK, Weigman V, Yaari G, Panzer JA, Friedman N, Maris JM. PMID: 37537844; PMCID: PMC10551040.
-
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 08; 70(8):e30418. Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, London WB, Park JR, Yanik GA, Naranjo A. PMID: 37199022; PMCID: PMC10511015.
-
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 05; 29(5):1092-1102. Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. PMID: 37012551; PMCID: PMC10202811.
-
Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. Int J Radiat Oncol Biol Phys. 2023 04 01; 115(5):1115-1128. Campbell K, Groshen S, Evans AC, Wilson S, Sebastian A, Loots GG, Marachelian A, Armant M, Pal S, Haas-Kogan DA, Park JR, Granger M, Matthay KK, Coleman MA, DuBois SG. PMID: 36526235.
-
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 11 01; 128(21):3775-3783. Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. PMID: 36101004; PMCID: PMC9614386.
-
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 12 10; 40(35):4107-4118. Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. PMID: 35839426; PMCID: PMC9746736.
-
Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022 08; 19(8):515-533. Qiu B, Matthay KK. PMID: 35614230.
-
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 09; 69(9):e29616. Vo KT, DuBois SG, Neuhaus J, Braunstein SE, Weil BR, Naranjo A, Irtan S, Balaguer J, Matthay KK. PMID: 35188340; PMCID: PMC9329207.
-
Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiat Res. 2022 Feb 01; 197(2):101-112. Evans AC, Setzkorn T, Edmondson DA, Segelke H, Wilson PF, Matthay KK, Granger MM, Marachelian A, Haas-Kogan DA, DuBois SG, Coleman MA. PMID: 34673986; PMCID: PMC8870530.
-
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries. Pediatr Blood Cancer. 2022 04; 69(4):e29568. Matthay KK, Hylton J, Penumarthy N, Khattab M, Soh SY, Nguyen HTK, Alcasabas AP, Fawzy M, Saab R, Khan MS, Ghandour K, Chantada G, Parikh NS, Faulkner L, Lam CG, Howard SC. PMID: 35084087.
-
Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. Pediatr Blood Cancer. 2022 02; 69(2):e29396. Fishel Ben Kenan R, Polishchuk AL, Hawkins RA, Braunstein SE, Matthay KK, DuBois SG, Haas-Kogan DA. PMID: 34662499.
-
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. PMID: 34270348; PMCID: PMC8547934.
-
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2021 10; 68(10):e29117. Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. PMID: 34028986; PMCID: PMC9150928.
-
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. PMID: 33504555; PMCID: PMC8046731.
-
Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. Cancer Med. 2021 04; 10(7):2232-2241. Temple WC, Vo KT, Matthay KK, Balliu B, Coleman C, Michlitsch J, Phelps A, Behr S, Zapala MA. PMID: 33314708; PMCID: PMC7982630.
-
Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654. Lavergne V, Sabnis A, Tupule A, Davidson PR, Kline C, Matthay K, Nicolaides T, Goldsby R, Braunstein S, Fogh SE, Sneed PK, Menzel P, Nakamura A, DuBois SG, Haas-Kogan DA, Nakamura JL. PMID: 31815884.
-
124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. J Nucl Med. 2021 01; 62(1):43-47. Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, Vo KT, Gustafson WC, Matthay KK, Seo Y. PMID: 32414950; PMCID: PMC9364877.
-
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. J Natl Cancer Inst. 2019 11 01; 111(11):1192-1201. Oldridge DA, Truong B, Russ D, DuBois SG, Vaksman Z, Mosse YP, Diskin SJ, Maris JM, Matthay KK. PMID: 30793172; PMCID: PMC6855946.
-
Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. J Clin Oncol. 2019 11 01; 37(31):2883-2891. Chévez-Barrios P, Eagle RC, Krailo M, Piao J, Albert DM, Gao Y, Vemuganti G, Ali MJ, Khetan V, Honavar SG, O'Brien J, Leahey AM, Matthay K, Meadows A, Chintagumpala M. PMID: 31539297; PMCID: PMC6823888.
-
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. PMID: 31386611; PMCID: PMC6881103.
-
Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review. Pediatr Blood Cancer. 2019 10; 66(10):e27901. Sznewajs A, Pon E, Matthay KK. PMID: 31264798.
-
Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biol Blood Marrow Transplant. 2019 10; 25(10):2031-2039. Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT. PMID: 31199983; PMCID: PMC9161973.
-
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 08; 66(8):e27819. Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG. PMID: 31115156; PMCID: PMC7323455.
-
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. PMID: 30968542; PMCID: PMC7281832.
-
Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT. Med Phys. 2019 May; 46(5):2477-2486. Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK. PMID: 30761545; PMCID: PMC6510622.
-
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. PMID: 30444686; PMCID: PMC6325354.
-
Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful? Lancet Oncol. 2018 12; 19(12):1549-1551. Matthay KK. PMID: 30442498.
-
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. PMID: 30093449; PMCID: PMC6295246.
-
Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives. Cureus. 2018 Apr 24; 10(4):e2527. Kumar P, Gill RM, Phelps A, Tulpule A, Matthay K, Nicolaides T. PMID: 29946497; PMCID: PMC6017131.
-
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023. Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. PMID: 29603591; PMCID: PMC6040651.
-
Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018 05; 372(2):195-209. Tolbert VP, Matthay KK. PMID: 29572647; PMCID: PMC5918153.
-
Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 05; 65(5):e26940. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. PMID: 29350464; PMCID: PMC7456604.
-
Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography. Interv Neuroradiol. 2018 Apr; 24(2):214-219. Kondapavulur S, Cooke DL, Kao A, Amans MR, Alexander M, Darflinger R, Dowd CF, Higashida RT, Damato B, Halbach VV, Matthay KK, Hetts SW. PMID: 29343147; PMCID: PMC5847018.
-
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34. de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. PMID: 29376112; PMCID: PMC5783315.
-
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. PMID: 28972044; PMCID: PMC5754221.
-
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018 Feb; 45(2):292-305. Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Sliwinska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A. PMID: 28940046; PMCID: PMC5747549.
-
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018 03; 59(3):502-508. Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK. PMID: 28887399; PMCID: PMC5868501.
-
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Nov 01; 123(21):4224-4235. Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG. PMID: 28696504; PMCID: PMC5650521.
-
Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. PMID: 28559462.
-
Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):468-475. Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG. PMID: 28871998.
-
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. PMID: 28471719; PMCID: PMC5676955.
-
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Nov; 64(11). DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, Matthay KK, Yanik G. PMID: 28383813; PMCID: PMC5605392.
-
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr 04; 8(14):23851-23861. Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. PMID: 27793021; PMCID: PMC5410349.
-
Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. J Pediatr Hematol Oncol. 2017 03; 39(2):108-113. Dinh T, Truong B, Matthay KK, DuBois SG. PMID: 27820129.
-
Neuroblastoma. Nat Rev Dis Primers. 2016 11 10; 2:16078. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. PMID: 27830764.
-
Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ. PMID: 28068235.
-
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 10; 66:144-52. Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. PMID: 27573428; PMCID: PMC7523915.
-
Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide. Radiat Res. 2016 09; 186(3):235-44. Edmondson DA, Karski EE, Kohlgruber A, Koneru H, Matthay KK, Allen S, Hartmann CL, Peterson LE, DuBois SG, Coleman MA. PMID: 27556353; PMCID: PMC5047008.
-
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. PMID: 27434878.
-
Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? Pediatr Blood Cancer. 2016 10; 63(10):1868. Lee JS, Matthay K, DuBois SG, Roy-Burman A. PMID: 27394054.
-
Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Jul; 43(7):1396. Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. PMID: 27044383.
-
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016; 6:9. Vo KT, Matthay KK, DuBois SG. PMID: 27274393; PMCID: PMC4896001.
-
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. PMID: 27092812; PMCID: PMC8992729.
-
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. PMID: 26884555; PMCID: PMC4872349.
-
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50. Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG. PMID: 26861456; PMCID: PMC4947459.
-
Physician Perspectives on Palliative Care for Children With Neuroblastoma: An International Context. Pediatr Blood Cancer. 2016 May; 63(5):872-9. Balkin EM, Thompson D, Colson KE, Lam CG, Matthay KK. PMID: 26784890.
-
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15; 122(6):935-45. Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. PMID: 26709890; PMCID: PMC4777644.
-
Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):471-8. Lee JS, Wu R, Wong T, DuBois SG, Matthay K, Gustafson C, Hawkins R, Roy-Burman A. PMID: 26585842.
-
Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. Pediatr Blood Cancer. 2016 Mar; 63(3):458-64. Cohler C, Jumanne S, Kaijage J, DuBois SG, Scanlan P, Matthay KK. PMID: 26529141.
-
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. PMID: 26506090; PMCID: PMC7523914.
-
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Mar; 43(3):474-481. Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. PMID: 26338179; PMCID: PMC4733400.
-
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. PMID: 26304901; PMCID: PMC4567703.
-
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov; 51(16):2465-72. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. PMID: 26254811; PMCID: PMC4607645.
-
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015 Oct; 62(10):1739-46. Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. PMID: 26153194.
-
Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015 Apr; 17(2):284-94. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y. PMID: 25145966; PMCID: PMC4336853.
-
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015 Aug; 62(8):1305-16. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK, International Society of Pediatric Oncology. PMID: 25810263; PMCID: PMC5132052.
-
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. PMID: 25695691; PMCID: PMC4470833.
-
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. PMID: 25639769.
-
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015 Feb 17; 112(4):644-9. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK. PMID: 25602966; PMCID: PMC4333502.
-
Reply to N.-K.V. Cheung et al. J Clin Oncol. 2014 Dec 20; 32(36):4174-5. Matthay KK, London WB, Maris J, Adamson PC, Park JR. PMID: 25403223; PMCID: PMC5142206.
-
Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma. 2014; 2014:902620. Thampi S, Matthay KK, Boscardin WJ, Goldsby R, DuBois SG. PMID: 25294959; PMCID: PMC4175789.
-
Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 08; 26(3):414-427. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. PMID: 25175806; PMCID: PMC4160413.
-
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. PMID: 25154816; PMCID: PMC4171360.
-
Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med. 2014 Oct; 40(10):1536-44. Zinter MS, DuBois SG, Spicer A, Matthay K, Sapru A. PMID: 25023526; PMCID: PMC4177269.
-
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. PMID: 25044743.
-
Symptom assessment in pediatric oncology: how should concordance between children's and parents' reports be evaluated? Cancer Nurs. 2014 Jul-Aug; 37(4):252-62. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. PMID: 24936750.
-
Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):839-45. Polishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA. PMID: 24867534.
-
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014 Apr 23; 7:256. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. PMID: 24755475; PMCID: PMC4006848.
-
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. PMID: 24663047; PMCID: PMC4876342.
-
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35. Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK. PMID: 24038992.
-
Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatr Blood Cancer. 2013 Dec; 60(12):2047-53. Kersten E, Scanlan P, Dubois SG, Matthay KK. PMID: 24039163.
-
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. PMID: 23890779; PMCID: PMC3963485.
-
Adverse impact of regional lymph node involvement in osteosarcoma. Eur J Cancer. 2013 Nov; 49(16):3471-6. Thampi S, Matthay KK, Goldsby R, DuBois SG. PMID: 23867123.
-
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. PMID: 23813912; PMCID: PMC4066886.
-
Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013; 7:981-9. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, Dubois SG, Char D, Halbach V, Matthay K. PMID: 23818751; PMCID: PMC3693581.
-
Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2013 Sep; 60(9):1424-30. Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG. PMID: 23613447.
-
131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013 Mar; 57(1):53-65. DuBois SG, Matthay KK. PMID: 23474635.
-
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013 Mar; 33(3):755-62. Mueller S, Bhargava S, Molinaro AM, Yang X, Kolkowitz I, Olow A, Wehmeijer N, Orbach S, Chen J, Matthay KK, Haas-Kogan DA. PMID: 23482742; PMCID: PMC3684561.
-
Infections in hospitalized children and young adults with acute leukemia in Morocco. Pediatr Blood Cancer. 2013 Jun; 60(6):916-22. Depasse J, Caniza MA, Quessar A, Khattab M, Hessissen L, Ribeiro R, Cherkaoui S, Benchekroun S, Matthay KK. PMID: 23450753.
-
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. PMID: 23440556; PMCID: PMC5503147.
-
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1083-94. Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. PMID: 23418018; PMCID: PMC3810072.
-
Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clin Cancer Res. 2013 Jan 15; 19(2):311-3. Matthay KK. PMID: 23209029; PMCID: PMC5892183.
-
Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012 Dec; 14(6):735-42. Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. PMID: 22382618; PMCID: PMC3369020.
-
131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May; 60(5):879-84. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. PMID: 23024113.
-
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834. Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. PMID: 23050139; PMCID: PMC3463166.
-
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD. PMID: 22976801; PMCID: PMC3494425.
-
Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33. Karski EE, Matthay KK, Neuhaus JM, Goldsby RE, Dubois SG. PMID: 22959474; PMCID: PMC3543501.
-
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012 Oct 01; 30(28):3525-32. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. PMID: 22927533; PMCID: PMC3675667.
-
Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Jul 19; 27(2):e164-6. Applebaum MA, Sambrano E, Lee S, Goldsby R, Matthay KK, DuBois SG. PMID: 22610756; PMCID: PMC4222526.
-
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. PMID: 22700000; PMCID: PMC12507347.
-
Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012 May 15; 18(10):2740-53. Matthay KK, George RE, Yu AL. PMID: 22589483; PMCID: PMC3382042.
-
Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42. Porzig A, Matthay KK, Dubois S, Pampaloni M, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. PMID: 22588707.
-
The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. PMID: 22493777.
-
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. PMID: 22529259; PMCID: PMC3383182.
-
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. PMID: 22421195; PMCID: PMC6814395.
-
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med. 2012 Jan 04; 4(115):115ra3. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. PMID: 22218692; PMCID: PMC3402217.
-
Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy. Cancer Nurs. 2012 Jan-Feb; 35(1):19-28. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. PMID: 21921793; PMCID: PMC3237960.
-
Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer. 2012 Oct; 59(4):611-6. Sharib JM, Cyrus J, Horvai A, Gray Hazard FK, Neuhaus J, Matthay KK, Goldsby R, Marina N, DuBois SG. PMID: 22180320; PMCID: PMC3310949.
-
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. Eur J Cancer. 2012 May; 48(8):1185-91. Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. PMID: 22137163.
-
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. PMID: 22010014; PMCID: PMC3221519.
-
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64. Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. PMID: 21969516; PMCID: PMC3221520.
-
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother. 2011 Oct; 11(10):1411-23. Gustafson WC, Matthay KK. PMID: 21955198.
-
Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2012 Jul 15; 59(1):52-6. DuBois SG, Goldsby R, Segal M, Woo J, Copren K, Kane JP, Pullinger CR, Matthay KK, Witte J, Lessnick SL, Robison LL, Bhatia S, Strong LC. PMID: 21793187; PMCID: PMC3204324.
-
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. PMID: 21768459; PMCID: PMC3158599.
-
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct; 261(1):243-57. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T, International Neuroblastoma Risk Group Project. PMID: 21586679.
-
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA. PMID: 21497989; PMCID: PMC3244077.
-
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49. More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK, Giacomini KM. PMID: 21421857; PMCID: PMC3247296.
-
Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011 Sep 15; 117(18):4286-93. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. PMID: 21387264; PMCID: PMC3125487.
-
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. PMID: 21340605; PMCID: PMC4238911.
-
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1041-5. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA. PMID: 21328522; PMCID: PMC4581540.
-
Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011 Jul 01; 117(13):3027-32. Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, Dubois SG. PMID: 21692057; PMCID: PMC3135782.
-
Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):449-53. Worch J, Cyrus J, Goldsby R, Matthay KK, Neuhaus J, DuBois SG. PMID: 21212061; PMCID: PMC3051020.
-
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011 Mar; 47(4):561-71. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. PMID: 21112770.
-
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. PMID: 21671363; PMCID: PMC3117015.
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group. PMID: 20879881; PMCID: PMC3086629.
-
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, Children’s Oncology Group. PMID: 20879880; PMCID: PMC2993160.
-
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011 Feb; 56(2):191-201. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK. PMID: 20830775; PMCID: PMC3006009.
-
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-7. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y. PMID: 20964203; PMCID: PMC2937055.
-
Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. J Pediatr Oncol Nurs. 2010 Nov-Dec; 27(6):307-15. Baggott C, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper BA, Miaskowski C. PMID: 20739586.
-
Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer. 2010 Aug; 55(2):285-9. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG. PMID: 20582978; PMCID: PMC2917386.
-
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010 Aug 20; 28(24):3808-15. London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L. PMID: 20660830; PMCID: PMC2940398.
-
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010 Apr 27; 102(9):1319-26. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson AD, Cohn SL. PMID: 20424613; PMCID: PMC2865749.
-
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr; 54(4):596-602. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. PMID: 20049927; PMCID: PMC2905158.
-
An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy. Support Care Cancer. 2011 Mar; 19(3):353-61. Baggott CR, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper B, Miaskowski C. PMID: 20157746; PMCID: PMC2909452.
-
Ethnic and racial differences in patients with Ewing sarcoma. Cancer. 2010 Feb 15; 116(4):983-8. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG. PMID: 20052725; PMCID: PMC2819622.
-
Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer. 2010 Jan; 54(1):13-8. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. PMID: 19711435; PMCID: PMC2846759.
-
Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: analysis of the surveillance, epidemiology, and end results database. J Pediatr Hematol Oncol. 2009 Dec; 31(12):942-6. Hsieh MH, Meng MV, Walsh TJ, Matthay KK, Baskin LS. PMID: 19875967.
-
Neuroblastoma: biology and staging. Curr Oncol Rep. 2009 Nov; 11(6):431-8. Mueller S, Matthay KK. PMID: 19840520.
-
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009 Nov 10; 27(32):5343-9. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. PMID: 19805691; PMCID: PMC2773221.
-
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer. 2009 Oct; 53(4):563-9. Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, Shimada H. PMID: 19530234; PMCID: PMC2730988.
-
Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Pediatr Radiol. 2009 Nov; 39(11):1194-202. Sutton EJ, Tong RT, Gillis AM, Henning TD, Weinberg VA, Boddington S, Haas-Kogan DA, Matthay K, Sha V, Gooding C, Coakley FV, Daldrup-Link H. PMID: 19763559; PMCID: PMC2765626.
-
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009 Sep 01; 27(25):4162-8. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P. PMID: 19636009; PMCID: PMC2734428.
-
Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):177-82. Jabbari S, Andolino D, Weinberg V, Missett BT, Law J, Wara WM, O'Donnell RJ, Matthay KK, DuBois SG, Goldsby R, Haas-Kogan DA. PMID: 19410386.
-
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009 May 19; 100(10):1627-37. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK, International neuroblastoma Risk Group Task Force. PMID: 19401690; PMCID: PMC2696761.
-
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 01; 27(7):1007-13. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. PMID: 19171716; PMCID: PMC2738615.
-
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 01; 27(7):1020-5. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. PMID: 19171714; PMCID: PMC2738616.
-
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol. 2009 Mar 10; 27(8):1290-6. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. PMID: 19171709; PMCID: PMC2667827.
-
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK, Children's Oncology Group. PMID: 18937318; PMCID: PMC2731719.
-
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10; 27(2):289-97. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force. PMID: 19047291; PMCID: PMC2650388.
-
Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008 Dec; 52(4):403-18. Taggart D, Dubois S, Matthay KK. PMID: 19088694.
-
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10; 27(2):298-303. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force. PMID: 19047290; PMCID: PMC2650389.
-
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009 Jan 20; 27(3):365-70. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL, International Neuroblastoma Risk Group. PMID: 19047282; PMCID: PMC2651034.
-
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009 Jan 01; 27(1):85-91. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM. PMID: 19047298; PMCID: PMC2645092.
-
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009 Jul; 64(2):243-51. Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL. PMID: 19020877.
-
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia. 2008 Nov; 10(11):1268-74. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. PMID: 18953436; PMCID: PMC2570603.
-
Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92. Dubois SG, London WB, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A, Diller L. PMID: 18649370; PMCID: PMC2746936.
-
Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2008 Nov; 35(11):2105-12. Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D, Normolle D, Yanik GA. PMID: 18682939.
-
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008 Aug; 35 Suppl 1:S35-48. DuBois SG, Matthay KK. PMID: 18707633; PMCID: PMC2633223.
-
Chemotherapy for neuroblastoma: does it hit the target? Lancet Oncol. 2008 Mar; 9(3):195-6. Matthay KK. PMID: 18308243.
-
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem. 2007 Dec 15; 102(6):1529-41. Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM. PMID: 17486636; PMCID: PMC3001106.
-
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics. 2007 Nov; 120(5):e1229-36. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML, Children's Oncology Group. PMID: 17974716.
-
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr Blood Cancer. 2007 Oct 15; 49(5):661-5. Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK, Balis FM. PMID: 16900483.
-
Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):858-64. Gillis AM, Sutton E, Dewitt KD, Matthay KK, Weinberg V, Fisch BM, Chan A, Gooding C, Daldrup-Link H, Wara WM, Farmer DL, Harrison MR, Haas-Kogan D. PMID: 17517478.
-
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007 Mar 20; 25(9):1054-60. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM. PMID: 17369569.
-
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006 Dec; 47(7):865-74. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK. PMID: 16444675.
-
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006 Sep 06; 98(17):1193-203. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. PMID: 16954472.
-
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006 Aug 15; 66(16):8139-46. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. PMID: 16912192; PMCID: PMC2924674.
-
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006 Aug; 1073:465-90. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK. PMID: 17102115.
-
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. PMID: 16778177.
-
International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. Eur J Cancer. 2006 May; 42(8):1113-9. Sano H, Bonadio J, Gerbing RB, London WB, Matthay KK, Lukens JN, Shimada H. PMID: 16624549.
-
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006 Mar 15; 12(6):1750-9. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, Children's Oncology Group. PMID: 16551859; PMCID: PMC2587020.
-
Is liver metastasis in neuroblastoma an indication for treatment reduction? Pediatr Blood Cancer. 2006 Mar; 46(3):269-70. Matthay KK. PMID: 16261577.
-
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20; 24(3):500-6. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. PMID: 16421427.
-
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005 Nov 24; 353(21):2243-53. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM, Children's Oncology Group. PMID: 16306521.
-
Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005 Oct 18; 228(1-2):275-82. Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, Pike M, Pistoia V. PMID: 15922508.
-
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett. 2005 Oct 18; 228(1-2):257-66. London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL, De Bernardi B. PMID: 16024170.
-
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005 Sep 20; 23(27):6474-80. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. PMID: 16116154.
-
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20; 23(27):6459-65. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. PMID: 16116153.
-
Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer. 2005 Mar; 44(3):232-9. Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK. PMID: 15490487.
-
Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer. 2005 Jan 01; 103(1):174-80. Kobayashi C, Monforte-Munoz HL, Gerbing RB, Stram DO, Matthay KK, Lukens JN, Seeger RC, Shimada H. PMID: 15549714.
-
TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer. 2004 Oct 15; 101(8):1873-81. Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC. PMID: 15386308.
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004 Jun 15; 22(12):2452-60. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK. PMID: 15197208.
-
Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg. 2004 Jun; 39(6):931-6. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. PMID: 15185228.
-
Visual attention in long-term survivors of leukemia receiving cranial radiation therapy. J Int Neuropsychol Soc. 2004 Mar; 10(2):211-20. Schatz J, Kramer JH, Ablin AR, Matthay KK. PMID: 15012841.
-
Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs. 2004; 6(2):107-22. Goldsby RE, Matthay KK. PMID: 15035651.
-
Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003 Nov 15; 98(10):2274-81. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H. PMID: 14601099.
-
Immune reconstitution, infectious complications and post transplant supportive care measures after autologous blood and marrow transplantation in children. Bone Marrow Transplant. 2003 Oct; 32(7):687-93. Machatschek J, Duda J, Matthay K, Cowan M, Horn B. PMID: 13130316.
-
Online exclusive: behavioral adjustment of children and adolescents with cancer: teacher, parent, and self-report. Oncol Nurs Forum. 2003 Sep-Oct; 30(5):E84-91. Moore IM, Challinor J, Pasvogel A, Matthay K, Hutter J, Kaemingk K. PMID: 12949601.
-
Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003 Jul 18; 197(1-2):185-92. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. PMID: 12880980.
-
High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003 Jul 15; 98(2):239-48. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. PMID: 12872341.
-
Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003 Jul; 25(7):543-7. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. PMID: 12847321.
-
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003 Jul 01; 98(1):155-65. Matthay KK, Brisse H, Couanet D, Couturier J, Bénard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J. PMID: 12833468.
-
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003 Jul 01; 21(13):2486-91. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. PMID: 12829667.
-
Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). Blood. 2003 Jun 01; 101(11):4640-1. McHale CM, Wiemels JL, Wiemels JL, Zhang L, Ma X, Buffler PA, Feusner J, Matthay K, Dahl G, Smith MT. PMID: 12756163.
-
Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):28-39. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, Stram DO, Matthay KK. PMID: 12694821.
-
Development and testing of the School Competency Assessment Scale. J Pediatr Oncol Nurs. 2003 Mar-Apr; 20(2):56-64. Challinor J, Moore IK, Kramer R, Pasvogel A, Leung K, Amylon M, Hutter J, Matthay K. PMID: 12709932.
-
Daycare attendance and risk of childhood acute lymphoblastic leukaemia. Br J Cancer. 2002 May 06; 86(9):1419-24. Ma X, Buffler PA, Selvin S, Matthay KK, Wiencke JK, Wiemels JL, Reynolds P. PMID: 11986774; PMCID: PMC2375371.
-
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002 Apr 15; 20(8):2142-9. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ. PMID: 11956276.
-
Pediatric acute blastic natural killer cell leukemia. Leuk Lymphoma. 2002 Apr; 43(4):901-6. DuBois SG, Etzell JE, Matthay KK, Robbins E, Banerjee A. PMID: 12153184.
-
Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant. 2002 Mar; 29(5):409-15. Horn B, Reiss U, Matthay K, McMillan A, Cowan M. PMID: 11919731.
-
Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001 Nov 15; 92(10):2699-708. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. PMID: 11745206.
-
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001 Nov; 42(11):1713-21. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B. PMID: 11696644.
-
International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001 Nov 01; 92(9):2451-61. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK. PMID: 11745303.
-
Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr. 2001 Oct; 139(4):552-9. Hayward K, Jeremy RJ, Jenkins S, Barkovich AJ, Gultekin SH, Kramer J, Crittenden M, Matthay KK. PMID: 11598603.
-
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol. 2001 Jun; 36(6):612-22. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Matthay KK. PMID: 11344492.
-
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol. 2001 Jun; 36(6):623-9. Cooper R, Khakoo Y, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Nakagawa A, Shimada H. PMID: 11344493.
-
Functional and clinical outcomes of limb-sparing therapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):763-9. Bertucio CS, Wara WM, Matthay KK, Ablin AR, Johnston JO, O'Donnell RJ, Weinberg V, Haas-Kogan DA. PMID: 11172960.
-
Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis. AJR Am J Roentgenol. 2001 Mar; 176(3):755-9. Kammen BF, Matthay KK, Pacharn P, Gerbing R, Brasch RC, Gooding CA. PMID: 11222220.
-
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001 Mar 01; 91(5):680-6. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Bénard J, Hartmann O, Nicholson JC, Ross FM, Brinkschmidt C, Laureys G, Caron H, Matthay KK, Feuerstein BG, Speleman F. PMID: 11267980.
-
Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med. 2001 Feb; 42(2):237-47. Tang HR, Da Silva AJ, Matthay KK, Price DC, Huberty JP, Hawkins RA, Hasegawa BH. PMID: 11216522.
-
Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):28-31. Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. PMID: 11464899.
-
Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001 Jan; 119(1):41-8. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. PMID: 11146725.
-
Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):32-6. Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. PMID: 11464900.
-
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):24-7. Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM. PMID: 11464895.
-
Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol. 2001 Jan-Feb; 26(1):1-9. Espy KA, Moore IM, Kaufmann PM, Kramer JH, Matthay K, Hutter JJ. PMID: 11145727.
-
Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2000 Dec 15; 18(24):4067-76. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. PMID: 11118468.
-
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000 Dec 15; 18(24):4077-85. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. PMID: 11118469.
-
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol. 2000 Dec; 35(6):719-23. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, Matthay KK, Sanders JE. PMID: 11107155.
-
Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med Pediatr Oncol. 2000 Dec; 35(6):619-22. Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Reynolds CP. PMID: 11107131.
-
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):647-50. Choi LM, Kim NW, Zuo JJ, Gerbing R, Stram D, Lukens JN, Matthay KK, Seeger RC, Reynolds CP. PMID: 11107138.
-
MYCN expression in neuroblastoma: A mixed message? J Clin Oncol. 2000 Nov 01; 18(21):3591-4. Matthay KK. PMID: 11054431.
-
Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br J Cancer. 2000 Nov; 83(9):1121-3. Matthay KK, Reynolds CP. PMID: 11027422; PMCID: PMC2363592.
-
Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Semin Oncol Nurs. 2000 Nov; 16(4):279-90; discussion 291-9. Moore IM, Espy KA, Kaufmann P, Kramer J, Kaemingk K, Miketova P, Mollova N, Kaspar M, Pasvogel A, Schram K, Wara W, Hutter J, Matthay K. PMID: 11109272.
-
Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer. 2000 Sep 01; 89(5):1150-61. Umehara S, Nakagawa A, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Shimada H. PMID: 10964346.
-
Is adjuvant therapy ever warranted in localized neuroblastoma. J Pediatr Hematol Oncol. 2000 Sep-Oct; 22(5):399-402. Matthay KK, Stram D. PMID: 11037848.
-
Intraoperative radiation therapy for high-risk pediatric neuroblastoma. Int J Radiat Oncol Biol Phys. 2000 Jul 01; 47(4):985-92. Haas-Kogan DA, Fisch BM, Wara WM, Swift PS, Farmer DL, Harrison MR, Albanese C, Weinberg V, Matthay KK. PMID: 10863069.
-
Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):315-20. Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey LE, Dalmau J. PMID: 10959901.
-
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer. 2000 Jun 15; 88(12):2838-44. Fernandez MC, Krailo MD, Gerbing RR, Matthay KK. PMID: 10870069.
-
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol. 2000 May; 18(9):1888-99. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. PMID: 10784629.
-
Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. Neuropsychology. 2000 Apr; 14(2):189-200. Schatz J, Kramer JH, Ablin A, Matthay KK. PMID: 10791859.
-
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol. 2000 Mar; 18(6):1260-8. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. PMID: 10715296.
-
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000 Feb; 18(3):477-86. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. PMID: 10653863.
-
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol. 2000 Jan; 18(1):18-26. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. PMID: 10623689.
-
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14; 341(16):1165-73. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. PMID: 10519894.
-
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999 Sep 02; 18(35):4948-57. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM. PMID: 10490829.
-
The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999 Jul 15; 86(2):364-72. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. PMID: 10421273.
-
Molecular biology of neuroblastoma. J Clin Oncol. 1999 Jul; 17(7):2264-79. Maris JM, Matthay KK. PMID: 10561284.
-
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun; 21(3):181-9. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO, Matthay KK. PMID: 10363850.
-
Congenital leukemia: successful treatment of a newborn with t(5;11)(q31;q23). J Pediatr Hematol Oncol. 1999 Mar-Apr; 21(2):152-7. Fernandez MC, Weiss B, Atwater S, Shannon K, Matthay KK. PMID: 10206463.
-
Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant. 1999; 3 Suppl 1:72-7. Matthay KK. PMID: 10587975.
-
Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancer. Int J Cancer Suppl. 1999; 12:52-7. Challinor JM, Miaskowski CA, Franck LS, Slaughter RE, Matthay KK, Kramer RF, Veatch JJ, Paul SM, Amylon MD, Moore IM. PMID: 10679871.
-
Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol. 1998 Jun; 30(6):339-46. Goldberg SS, DeSantes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK. PMID: 9589082.
-
Stage 4S neuroblastoma: what makes it special? J Clin Oncol. 1998 Jun; 16(6):2003-6. Matthay KK. PMID: 9626196.
-
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998 Apr; 16(4):1256-64. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN. PMID: 9552023.
-
Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol. 1998 Mar; 16(3):937-44. Ozkaynak MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP, Buckley J, Villablanca JG, Seeger RC. PMID: 9508176.
-
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998 Jan; 16(1):229-36. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. PMID: 9440747.
-
Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein. Horm Res. 1998; 50(4):217-21. Loh K, Matthay KK, Hoover M, Bracho FA, Cortez AB, Conte FA, Albanese CT, Miller TR, Price DC, Flores AJ, Kaviani A, Shoback D. PMID: 9838243.
-
Neuroblastoma: biology and therapy. Oncology (Williston Park). 1997 Dec; 11(12):1857-66; discussion 1869-72, 1875. Matthay KK. PMID: 9436190.
-
The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997 Dec; 20(11):648-58. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. PMID: 9492103.
-
Telomerase expression in primary neuroblastomas. Eur J Cancer. 1997 Oct; 33(12):1929-31. Reynolds CP, Zuo JJ, Kim NW, Wang H, Lukens JN, Matthay KK, Seeger RC. PMID: 9516826.
-
The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997 Oct; 33(12):2113-6. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner P, Lee RE, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC, Shaw PJ, Shuster JJ, et al. PMID: 9516864.
-
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997 Jul 15; 80(2):317-33. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. PMID: 9217046.
-
Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol. 1997 Jan; 150(1):81-9. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. PMID: 9006325; PMCID: PMC1858505.
-
Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant. 1996 Dec; 18 Suppl 3:S21-4. Matthay KK. PMID: 8971402.
-
Renal cell carcinoma after therapy for neuroblastoma. AJR Am J Roentgenol. 1996 Oct; 167(4):915-7. Donnelly LF, Rencken IO, Shardell K, Matthay KK, Miller CR, Vartanian RK, Gooding CA. PMID: 8819382.
-
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996 Sep; 14(9):2417-26. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC. PMID: 8823319.
-
Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996 Jul; 14(7):2073-82. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. PMID: 8683239.
-
Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Med Pediatr Oncol. 1996 May; 26(5):329-33. Lang P, Vahlensieck M, Matthay KK, Johnston JO, Rosenau W, Gooding CA, Genant HK. PMID: 8614366.
-
Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience. Ann Surg Oncol. 1995 Nov; 2(6):516-23. Haase GM, O'Leary MC, Stram DO, Lukens JN, Seeger RC, Shimada H, Matthay KK. PMID: 8591082.
-
Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995 Oct 04; 87(19):1470-6. Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC. PMID: 7674334.
-
Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol. 1995 Jul; 165(1):135-42. Lang P, Grampp S, Vahlensieck M, Johnston JO, Honda G, Rosenau W, Matthay KK, Peterfy C, Higgins CB, Genant HK, et al. PMID: 7785572.
-
p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer. 1995 Jul 01; 76(1):57-66. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Göppinger A, Pfleiderer A. PMID: 8630877.
-
Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin. 1995 May-Jun; 45(3):179-92. Matthay KK. PMID: 7743421.
-
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995 Apr; 13(4):894-901. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP. PMID: 7707116.
-
Radiological case of the month. Miliary pulmonary neuroblastoma. Arch Pediatr Adolesc Med. 1995 Feb; 149(2):195-6. Kalra R, Zoger S, Kosovich MS, Matthay KK. PMID: 7849882.
-
Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg. 1995 Feb; 30(2):289-94; discussion 295. Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. PMID: 7738753.
-
Hematology and oncology. Curr Opin Pediatr. 1995 Feb; 7(1):33-5. Mentzer WC, Matthay K. PMID: 7728200.
-
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995; 31A(4):572-5. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC. PMID: 7576971.
-
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol. 1994 Nov; 12(11):2382-9. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, Selch M, Atkinson JB, Haase GM, Ramsay NK. PMID: 7964954.
-
Normal cerebellar MIBG localization. Implications in the interpretation of delayed scans. Clin Nucl Med. 1994 Nov; 19(11):985-8. Hattner RS, Pounds TR, Matthay KK. PMID: 7842595.
-
Hematology and oncology. Curr Opin Pediatr. 1994 Feb; 6(1):43-5. Mentzer WC, Matthay K. PMID: 8205173.
-
Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Prog Clin Biol Res. 1994; 385:301-7. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary M, Harris RE, Selch M, Atkinson JB, Haase G, Hammond GD, et al. PMID: 7972225.
-
Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res. 1994; 385:287-91. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Seeger RC. PMID: 7972222.
-
Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med. 1993 Nov; 34(11):1922-6. Parisi MT, Hattner RS, Matthay KK, Berg BO, Sandler ED. PMID: 8229235.
-
Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993 Nov; 11(11):2226-33. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. PMID: 8229138.
-
Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol. 1993 Apr; 11(4):623-9. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. PMID: 8478657.
-
Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology. 1992 Aug; 184(2):463-7. Parisi MT, Matthay KK, Huberty JP, Hattner RS. PMID: 1620849.
-
Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):4207-9. Iavarone A, Matthay KK, Steinkirchner TM, Israel MA. PMID: 1349175; PMCID: PMC525662.
-
Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta. 1992 Apr 13; 1105(2):193-200. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ, Papahadjopoulos D. PMID: 1586658.
-
Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys. 1992; 22(1):13-6. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. PMID: 1727109.
-
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991 Dec 15; 88(24):11460-4. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, et al. PMID: 1763060; PMCID: PMC53155.
-
Role of radiotherapy in neuroblastoma. J Clin Oncol. 1991 Nov; 9(11):2076-7. D'Angio GJ, Matthay KK, Evans AE. PMID: 1941067.
-
An overview on the treatment of neuroblastoma. J Nucl Biol Med (1991). 1991 Oct-Dec; 35(4):179-82. Matthay KK. PMID: 1823813.
-
Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med (1991). 1991 Oct-Dec; 35(4):244-7. Matthay KK, Huberty JP, Hattner RS, Ablin AR, Engelstad BL, Zoger S, Hasegawa BH, Price D. PMID: 1823827.
-
Solid tumors in children. N Engl J Med. 1991 Sep 12; 325(11):813-4. D'Angio GJ, Matthay KK. PMID: 1870659.
-
Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991; 366:527-33. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N, Reynolds CP. PMID: 2068169.
-
Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res. 1991; 366:203-11. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC. PMID: 2068138.
-
Hematologic disorders affecting the lungs. Clin Chest Med. 1989 Dec; 10(4):723-46. Edwards JR, Matthay KK. PMID: 2689072.
-
Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. Blood. 1989 Nov 01; 74(6):2043-52. Hege KM, Daleke DL, Waldmann TA, Matthay KK. PMID: 2679914.
-
Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res. 1989 Sep 01; 49(17):4879-86. Matthay KK, Abai AM, Cobb S, Hong K, Papahadjopoulos D, Straubinger RM. PMID: 2788031.
-
Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989 Feb; 7(2):236-44. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. PMID: 2915240.
-
Ewing's sarcoma of the mandible. Otolaryngol Head Neck Surg. 1989 Jan; 100(1):74-7. Langman AW, Kaplan MJ, Matthay K. PMID: 2493621.
-
Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer. 1988 Aug 15; 62(4):818-25. Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. PMID: 3293764.
-
Childhood acute lymphoblastic leukemia. Pediatr Ann. 1988 Mar; 17(3):156-61, 164-70. Diamond CA, Matthay KK. PMID: 3281103.
-
Patient, parent, and physician perspectives on pediatric oncology rounds. J Pediatr. 1988 Mar; 112(3):378-84. Lewis C, Knopf D, Chastain-Lorber K, Ablin A, Zoger S, Matthay K, Glasser M, Pantell R. PMID: 3346775.
-
Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. Cancer Res. 1987 Nov 15; 47(22):5954-9. Berinstein N, Matthay KK, Papahadjopoulos D, Levy R, Sikic BI. PMID: 3664498.
-
Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery. Cancer Res. 1986 Oct; 46(10):4904-10. Matthay KK, Heath TD, Badger CC, Bernstein ID, Papahadjopoulos D. PMID: 3756852.
-
Bone marrow in children with acute lymphocytic leukemia: MR relaxation times. Radiology. 1986 Jul; 160(1):237-40. Moore SG, Gooding CA, Brasch RC, Ehman RL, Ringertz HG, Ablin AR, Matthay KK, Zoger S. PMID: 3459212.
-
New methodology for liposome targeting to specific cells. Ann N Y Acad Sci. 1985; 446:341-8. Papahadjopoulos D, Heath T, Bragman K, Matthay K. PMID: 2861775.
-
Monoclonal antibodies in the diagnosis and treatment of childhood diseases. Adv Pediatr. 1985; 32:101-37. Matthay KK. PMID: 3909771.
-
Spinal cord compression in a child with acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1985; 7(4):373-6. Lo WD, Matthay KK, Kushner J. PMID: 3866496.
-
Long-term follow-up and booster immunization with polyvalent pneumococcal polysaccharide in patients with sickle cell anemia. J Pediatr. 1984 Aug; 105(2):261-3. Weintrub PS, Schiffman G, Addiego JE, Matthay KK, Vichinsky E, Johnson R, Lubin B, Mentzer WC, Ammann AJ. PMID: 6747758.
-
Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles. Cancer Res. 1984 May; 44(5):1880-6. Matthay KK, Heath TD, Papahadjopoulos D. PMID: 6713389.
-
Prenatal diagnosis of chronic granulomatous disease. Am J Med Genet. 1984 Apr; 17(4):731-9. Matthay KK, Golbus MS, Wara DW, Mentzer WC. PMID: 6720741.
-
Antibody-directed liposomes: the development of a cell-specific cytotoxic agent. Biochem Soc Trans. 1984 Apr; 12(2):340-2. Heath TD, Bragman KS, Matthay KK, Lopez-Straubinger NG, Papahadjopoulos D. PMID: 6724119.
-
Increased serum opsonic activity and antibody concentration in patients with sickle cell disease after pneumococcal polysaccharide immunization. J Pediatr. 1983 Jan; 102(1):51-4. Chudwin DS, Wara DW, Matthay KK, Caulfield MH, Schiffmann G, Mentzer WC, Ammann AJ. PMID: 6848728.
-
Erythrocyte enzymopathies in the newborn. Clin Haematol. 1981 Feb; 10(1):31-55. Matthay KK, Mentzer WC. PMID: 7011626.
-
Modification of hemoglobin H disease by sickle trait. J Clin Invest. 1979 Oct; 64(4):1024-32. Matthay KK, Mentzer WC, Dozy AM, Kan YW, Bainton DF. PMID: 479366; PMCID: PMC372212.
-
Intracranial hemorrhage in congenital factor VII deficiency. J Pediatr. 1979 Mar; 94(3):413-5. Matthay KK, Koerper MA, Ablin AR. PMID: 423024.
US